AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04398056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy and Toripalimab
Description: 1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years.
Study NCT01528696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum.
Study NCT01528696 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dressing
Description: Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
Study NCT04408586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine-Topiramate Extended Release
Description: Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
Study NCT04408586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient
Study NCT04408586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online support system
Description: VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
Study NCT04408586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online support system
Description: VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
Study NCT01348438 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Engager Transcatheter Aortic Valve Implantation System
Description: Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
Study NCT04610307 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: buffered anesthesia
Description: patients will undergo surgery under buffered local anesthesia
Study NCT04610307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buffered anesthesia
Description: patients will undergo surgery under buffered local anesthesia
Study NCT03554590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: carbohydrate counting
Description: patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
Study NCT03554590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin therapy according to standard care
Description: patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
Study NCT02448550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Study NCT02448550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Study NCT04045912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGYW-Friendly Services
Description: Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW.
Study NCT04045912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIVST
Description: Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
Study NCT04045912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIVST
Description: Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
Study NCT02711371 — intervention group
Intervention type: OTHER
Intervention: fMRI
Study NCT01642537 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rhythmia Mapping System and the Rhythmia Mapping Catheter
Description: Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
Study NCT01979744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Description: Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
Study NCT01979744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Description: Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
Study NCT01979744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Description: Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
Study NCT01979744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Description: Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
Study NCT01561638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiofrequency
Description: pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
Study NCT01561638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Dose Radiofrequency
Description: pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
Study NCT01561638 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: will receive puncture for 4 minutes
Study NCT01325493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Study NCT01325493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Study NCT01953315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Progenitor Cells
Description: Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
Study NCT03025581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nipple stimulation
Description: For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
Study NCT02604966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) group
Description: Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
Study NCT02604966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA - PPQ group
Description: Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
Study NCT03669133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 800 IU/daily
Study NCT03669133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo daily
Study NCT02280811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
Study NCT02280811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
Study NCT02280811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E6 TCR
Description: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
Study NCT02280811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT04300725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Counseling
Description: Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
Study NCT01210443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan
Description: sitaxentan sodium 100 mg
Study NCT04103918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jalucomplex
Description: Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
Study NCT00770861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
Study NCT00770861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, oral administration
Study NCT03619122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Examination
Description: The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
Study NCT03229577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: Yoga-based breathing program.
Study NCT03229577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Mindfulness program.
Study NCT03229577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence
Description: Emotional Intelligence program.
Study NCT03899740 — intervention group
Intervention type: OTHER
Intervention: Brainstorming 1
Description: Expert recommendation statements will be collected for peer evaluation.
Study NCT03899740 — intervention group
Intervention type: OTHER
Intervention: Ranking - Round 1
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT03899740 — intervention group
Intervention type: OTHER
Intervention: Ranking - Round 2
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT04690647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Opioid and non opioid postoperative analgesia.
Description: Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
Study NCT04690647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid and non opioid postoperative analgesia.
Description: Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
Study NCT03899740 — intervention group
Intervention type: OTHER
Intervention: Ranking - Round 3
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT01872351 — intervention group
Intervention type: DRUG
Intervention: Nutraceuticals
Study NCT01570491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided spinal anesthesia
Description: ultrasound-guided technique for block placement
Study NCT01570491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard spinal anesthesia
Description: Anesthesiologist will use standard technique for placement of spinal block.
Study NCT01412242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive search for isolated calf DVT
Description: Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
Study NCT04690647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Description: Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
Study NCT04690647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
Study NCT02844608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
Study NCT00668967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: verapamil
Description: 240 mg extended release tablets once daily at bedtime for 28 days
Study NCT01905735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhustoxicodendron 30
Description: 1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
Study NCT01905735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
Study NCT02572713 — intervention group
Intervention type: PROCEDURE
Intervention: Biofluid samplings
Description: Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
Study NCT01522495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Description: Intravenous(1X) in conjunction with SPY Imaging (1 arm)
Study NCT02572713 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue samplings
Description: Tissue samplings (skin, colon, submandibular gland)
Study NCT02572713 — intervention group
Intervention type: DRUG
Intervention: DaTSCAN™
Study NCT00674882 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
Study NCT04163991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: liquid for IV infusion following dilution in normal saline
Study NCT03962439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Demand Photography
Description: The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
Study NCT03962439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Demand Photography
Description: The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
Study NCT03962439 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: At-Home Engagement
Description: The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
Study NCT00984022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Type of dressing - Iodoform
Description: Dressing for packing a cutaneous abscess
Study NCT00984022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Type of dressing - Aquacel
Description: Aquacel dressing
Study NCT02771353 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WT_vDIBH
Study NCT02771353 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VMAT_FB
Study NCT02648438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Solution for infusion (150 μg intravenous formulation)
Description: Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
Study NCT02648438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Oral suspension (1200 μg oral formulation)
Description: 0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
Study NCT02648438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
Description: Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
Study NCT02648438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
Description: Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
Study NCT02648438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Description: Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
Study NCT01131637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
Study NCT01131637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection